Denali Wins FDA Nod for Brain-Barrier Drug

Denali Therapeutics wins FDA accelerated approval for AVLAYAH, the first oligonucleotide to cross the blood-brain barrier via transferrin receptor

12 Jun 2026

A regulatory decision in March quietly redrew the map for brain medicine. The FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), a therapy from Denali Therapeutics that crosses the blood-brain barrier by hitching a ride on the transferrin receptor pathway. No oligonucleotide had done that before.

The drug targets the neurological symptoms of Hunter syndrome, a rare and brutal lysosomal storage disorder that affects young children and had long resisted meaningful treatment. Families managing the disease have had almost nothing to reach for neurologically. That calculus is now changing.

Denali moved fast after approval. The company launched commercially and treated its first patients in April 2026, a turnaround that matters enormously in rare pediatric disease, where delays carry a cost no family can afford. Real patients are already on therapy.

Deeper in Denali's pipeline, a compound called DNL628 targets tau protein linked to Alzheimer's disease, using the same transferrin receptor platform. First patient dosing has begun. Scaling this mechanism toward Alzheimer's puts the company in territory that could affect millions rather than thousands, and it marks a serious test of whether the platform holds at far greater reach.

For drug developers broadly, the implications run further than one company's pipeline. Getting large molecules across the blood-brain barrier has defeated pharma for decades. A validated commercial product changes what looks possible and will attract capital, competitors, and clinical ambition in roughly equal measure. Confirmatory trial data, required under the accelerated approval framework, will tell the market whether the science is as durable as the early results suggest.